Concord Wealth Partners’s Novavax NVAX Stock Holding History

Concord Wealth Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14	Closed	-$1K	–	1330
2022 Q1	$1K	Buy	+14	New	+$1.25K	﹤0.01%	1227
2021 Q1	–	Sell	-5	Closed	-$1K	–	1046
2020 Q4	$1K	Buy	+5	New	+$531	﹤0.01%	642

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Concord Wealth Partners's NVAX Position: Q2 2022 in Review

Concord Wealth Partners sold out of Novavax (NVAX) in Q2 2022, closing a stake of 14 shares — an estimated $1K sold.

Concord Wealth Partners first reported a position in NVAX in Q4 2020 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

Concord Wealth Partners reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
Concord Wealth Partners sold 14 Novavax shares in Q2 2022, an estimated $1K.
Concord Wealth Partners first reported a position in Novavax in Q4 2020 and held it in 2 quarters.
Concord Wealth Partners's Novavax position peaked at $1K in Q1 2022.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Concord Wealth Partners's 13F filing for Q2 2022, filed 4 Aug 2022.